France · Delayed Price · Currency is EUR Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 1.29 billion. The enterprise value is 1.29 billion.
| Market Cap | 1.29B |
| Enterprise Value | 1.29B |
Important Dates
The last earnings date was Friday, October 2, 2026.
| Earnings Date | Oct 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 50.81 million shares outstanding. The number of shares has increased by 2.40% in one year.
| Current Share Class | 50.81M |
| Shares Outstanding | 50.81M |
| Shares Change (YoY) | +2.40% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 3.97% |
| Owned by Institutions (%) | 15.09% |
| Float | 35.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 112.17 |
| PB Ratio | -38.66 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 111.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44
| Current Ratio | 1.44 |
| Quick Ratio | 1.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.03 |
| Interest Coverage | -1.43 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.34% |
| Return on Invested Capital (ROIC) | -66.69% |
| Return on Capital Employed (ROCE) | -69.86% |
| Weighted Average Cost of Capital (WACC) | 7.97% |
| Revenue Per Employee | 115,060 |
| Profits Per Employee | -528,660 |
| Employee Count | 100 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Nanobiotix has paid 13,000 in taxes.
| Income Tax | 13,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.94% in the last 52 weeks. The beta is 0.57, so Nanobiotix's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +40.94% |
| 50-Day Moving Average | 32.55 |
| 200-Day Moving Average | 28.76 |
| Relative Strength Index (RSI) | 23.96 |
| Average Volume (20 Days) | 157,890 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR 11.51 million and -52.87 million in losses. Loss per share was -1.09.
| Revenue | 11.51M |
| Gross Profit | 11.51M |
| Operating Income | -29.62M |
| Pretax Income | -52.85M |
| Net Income | -52.87M |
| EBITDA | -29.79M |
| EBIT | -29.62M |
| Loss Per Share | -1.09 |
Balance Sheet
The company has 110.89 million in cash and 106.61 million in debt, with a net cash position of 4.28 million or 0.08 per share.
| Cash & Cash Equivalents | 110.89M |
| Total Debt | 106.61M |
| Net Cash | 4.28M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | -33.38M |
| Book Value Per Share | -0.66 |
| Working Capital | 37.55M |
Cash Flow
In the last 12 months, operating cash flow was -34.19 million and capital expenditures -1.02 million, giving a free cash flow of -35.20 million.
| Operating Cash Flow | -34.19M |
| Capital Expenditures | -1.02M |
| Depreciation & Amortization | -166,000 |
| Net Borrowing | 38.54M |
| Free Cash Flow | -35.20M |
| FCF Per Share | -0.69 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -257.43% |
| Pretax Margin | -459.35% |
| Profit Margin | n/a |
| EBITDA Margin | -258.87% |
| EBIT Margin | -257.43% |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.40% |
| Shareholder Yield | -2.40% |
| Earnings Yield | -4.10% |
| FCF Yield | -2.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Nanobiotix is 52.20, which is 128.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 52.20 |
| Price Target Difference | 128.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 40.84% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of 2.89 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.89 |
| Piotroski F-Score | 2 |